<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505491</url>
  </required_header>
  <id_info>
    <org_study_id>1297.1</org_study_id>
    <nct_id>NCT01505491</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects</brief_title>
  <official_title>Pharmacokinetics and Safety of BI 695501 in Healthy Subjects: a Randomized, Open-label, Single Dose, Parallel Arm, Active Comparator Clinical Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This trial will investigate the pharmacokinetics, safety and tolerability of BI 695501 and to
      establish pharmacokinetic equivalence of BI 695501 to adalimumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</measure>
    <time_frame>72 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma</measure>
    <time_frame>72 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point</measure>
    <time_frame>72 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 14</measure>
    <time_frame>72 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal phase half life</measure>
    <time_frame>72 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of the analyte in the plasma after extravascular administration</measure>
    <time_frame>72 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">193</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 695501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adalimumab - US</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adalimumab - EU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>40mg adalimumab single s.c. injection</description>
    <arm_group_label>adalimumab - EU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI695501</intervention_name>
    <description>BI 695501 single s.c injection</description>
    <arm_group_label>BI 695501</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>40mg adalimumab single s.c. injection</description>
    <arm_group_label>adalimumab - US</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males

          2. Body mass index (BMI) =18.5 to =29.9 kg/m2

        Exclusion criteria:

          1. Any clinically relevant abnormal finding of the medical examination (including blood
             pressure, pulse rate and electrocardiogram) deviating from normal and of clinical
             relevance

          2. Any evidence of a clinically relevant previous or concomitant disease as judged by the
             investigator.

          3. Chronic or relevant acute infections. A negative result for Human Immunodeficiency
             Virus, Hepatitis B and Hepatitis C testing is required for participation.

          4. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          5. Intake of prescribed or over-the-counter drugs with a long half-life (&gt;24 hours)
             within at least one month or less than 5 half-lives of the respective drug prior to
             administration or during the trial

          6. Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

          7. Inability to refrain from smoking during days of confinement at the study center

          8. Alcohol abuse (average more than 30 g/day)

          9. Current drug abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1297.1.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1297.1.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

